Efalizumab-induced immune thrombocytopenia during retreatment

Journal of the American Academy of Dermatology

Volumn 58, Issue 5 SUPPL. 1, 2008, Pages

  Fargnoli, Maria Concetta ^a   Tabilio, Antonio ^a   Coletti, Gino ^b   Peris, Ketty ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b SAN SALVATORE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; EFALIZUMAB; PREDNISONE; RETINOID DERIVATIVE;

ADULT; ANAMNESIS; ARTICLE; BLOOD CELL COUNT; BONE MARROW BIOPSY; CASE REPORT; CLINICAL EVALUATION; HUMAN; HUMAN TISSUE; IMMUNE THROMBOCYTOPENIA; LABORATORY TEST; LOADING DRUG DOSE; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSORIASIS VULGARIS; RELAPSE; SCORING SYSTEM; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; HUMANS; MALE; PLATELET COUNT; PSORIASIS; THROMBOCYTOPENIA;

EID: 41849119784     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2007.07.025     Document Type: Article

References (3)

1. Dubertret L., Sterry W., Bos J.D., Chimenti S., Shumack S., Larsen C.G., et al. Clinical experience acquired with the efalizumab (Raptiva®) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol 155 (2006) 170-181
2. Warkentin T.E., and Kwon P. Immune thrombocytopenia associated with efalizumab therapy for psoriasis. Ann Intern Med 143 (2005) 761-762
3. Scheinfeld N. Efalizumab: a review of events reported during clinical trials and side effects. Expert Opin Drug Safety 5 (2006) 197-209